Paloma Partners’s Citius Pharmaceuticals CTXR Stock Holding History

Paloma Partners’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,902	Closed	-$27.8K	–	1258
2024 Q2	$27.8K	Buy	+1,902	New	+$34.1K	﹤0.01%	1169

Other funds holding CTXR

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CCC

Chelsea Counsel Company Los Angeles, California $225M AUM 45.99% 1-Year Est. Return

Paloma Partners's CTXR Position: Q3 2024 in Review

Paloma Partners sold out of Citius Pharmaceuticals (CTXR) in Q3 2024, closing a stake of 1,902 shares — an estimated $27.8K sold.

Paloma Partners first reported a position in CTXR in Q2 2024 and held it in 1 quarter. The position peaked at $27.8K in Q2 2024. 57 funds tracked by Wall St. Rank hold CTXR as of Q3 2024.

Paloma Partners reported no remaining Citius Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Paloma Partners sold 1,902 Citius Pharmaceuticals shares in Q3 2024, an estimated $27.8K.
Paloma Partners first reported a position in Citius Pharmaceuticals in Q2 2024 and held it in 1 quarter.
Paloma Partners's Citius Pharmaceuticals position peaked at $27.8K in Q2 2024.
57 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.